Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pertuzumab biosimilar - Zhejiang Hisun Pharmaceutical

Next Previous
Search
Drug Profile

Pertuzumab biosimilar - Zhejiang Hisun Pharmaceutical

Alternative Names: Anti-HER2 monoclonal antibody - Zhejiang Hisun Pharmaceutical; HS 627

Latest Information Update: 11 Oct 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zhejiang Hisun Pharmaceutical
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported HER2 positive breast cancer

Most Recent Events

  • 11 Oct 2022 No development reported - Phase-III for HER2-positive-breast-cancer (Combination therapy, Neoadjuvant therapy) in China (IV) (Zhejiang Hisun Pharmaceutical pipeline)
  • 09 Oct 2022 The Affiliated Hospital of Qingdao University completed a phase I trial in healthy volunteers in China (NCT05323981)
  • 11 Apr 2022 The Affiliated Hospital of Qingdao University initiated a phase I trial in healthy volunteers in China (NCT05323981)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top